The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 16th Jan 2013 07:16

Anglo American: Goldman Sachs reduces target price from 1650p to 1500p and reiterates its sell recommendation.Antofagasta: Goldman Sachs ups target price from 1100p to 1120p and still recommends to sell.ARM Holdings: UBS increases target price from 750p to 900p, while downgrading to neutral.Ashtead Group: Credit Suisse raises target price from 400p to 545p retaining an outperform rating.Balfour Beatty: Credit Suisse shifts target price from 275p to 279p and keeps a neutral rating.Barclays: Nomura ups target price from 230p to 270p maintaining a reduce rating.Barratt Developments: Panmure Gordon shifts target price from 211p to 220p and retains a hold recommendation.Berendsen: Credit Suisse increases target price from 640p to 710p and maintains an outperform rating.BHP Billiton: JP Morgan takes target price from 2245p to 2300p and keeps a neutral rating. Goldman Sachs ups target price from 2400p to 2450p, while its buy recommendation remains unchanged.Brammer: Jefferies raises target price from 295p to 340p and downgrades from buy to hold.BT Group: Deutsche Bank increases target price from 235p to 269p, while retaining a hold rating.Burberry Group: UBS moves target price from 1170p to 1350p and reiterates a neutral rating. Credit Suisse ups target price from 1430p to 1550p, while staying with its outperform rating. Berenberg takes price target from 1400p to 1600p keeping a buy recommendation.Capital Shopping Centres Group: JP Morgan increases target price from 380p to 400p and upgrades to neutral.Carillion: Credit Suisse ups target price from 316p to 349p and downgrades to neutral.Centrica: Barclays raises target price from 305p to 325p and keeps an underweight rating.Charlemagne Capital: JP Morgan shifts target price from 5p to 7p, while retaining an underweight rating.COLT Telecom Group: Deutsche Bank cuts target price from 155p to 145p, while its buy recommendation is reiterated.Communisis: Panmure Gordon downgrades from buy to hold with its target price still at 47p.Diageo: Nomura lowers target price from 2070p to 2040p, while the buy rating is kept. Societe Generale reduces target price from 2050p to 1900p and downgrades to hold.Eurasian Natural Resources Corporation: JP Morgan ups target price from 275p to 300p, while the neutral rating is maintained.Fenner: Investec shifts target price from 415p to 420p, while retaining a hold rating.French Connection: Seymour Pierce cuts target price from 25p to 20p still recommending to hold.Glaxo Smith Kline: Jefferies raises target price from 1450p to 1500p and reiterates a hold rating.Home Retail Group: Barclays shifts target price from 70p to 73p and retains an underweight rating.HSBC Holdings: Nomura increases target price from 660p to 730p staying with its buy recommendation.Intermediate Capital Group: Deutsche Bank ups target price from 298p to 322p and keeps a hold rating.ITV: JP Morgan moves target price from 109p to 120p and downgrades to neutral.Kazakhmys: Goldman Sachs cuts target price from 850p to 820p, while its neutral rating is reiterated.Liontrust Asset Management: JP Morgan ups target price from 112p to 134p, while keeping an underweight rating.Lonmin: After Lonmin has not been rated, Investec recommends to hold with its target price at 353p.Lloyds Banking Group: Nomura shifts target price from 37p to 42p and maintains a reduce rating.MITIE Group: Credit Suisse reduces target price from 290p to 250p and keeps an underperform rating.N Brown: Seymour Pierce moves target price from 280p to 360p reiterating its hold recommendation.Provident Financial: JP Morgan ups target price from 1626p to 1646p, while maintaining an overweight rating.Rio Tinto: UBS reduces target price from 4340p to 4320p keeping its buy recommendation. JP Morgan raises target price from 4200p to 4400p and reiterates an overweight rating. Goldman Sachs increases target price from 3400p to 3800p, while its neutral rating remains unchanged. Deutsche Bank lowers target price from 4520p to 4450p and maintains a buy recommendation. Morgan Stanley downgrades to equalweight. Rolls-Royce Group: Credit Suisse takes price target from 850p to 900p and retains a neutral rating.Royal Bank of Scotland: Nomura raises target price from 270p to 300p and stays with a reduce rating.RPS Group: Investec moves target price from 270p to 275p keeping a buy recommendation.SAB Miller: Nomura shifts target price from 2800p to 2840p maintaining a neutral rating.Signet Jewelers: UBS ups target price from 3700p to 4050p, while its buy recommendation remains unchanged.Standart Chartered: Nomura moves target price from 1600p to 1800p reiterating a buy rating.Tarsus Group: Investec takes price target from 210p to 215p, while its buy rating in unchanged.Thorntons: Investec increases target price from 30p to 45p and stays with a hold recommendation.Virgin Media: Deutsche Bank raises target price from 2325p to 3154p, while its buy recommendation is maintained.Vodafone: Deutsche Bank cuts target price from 225p to 175p and downgrades to hold.Wetherspoon JD: Investec lowers target price from 570p to 550p and retains its buy recommendation.
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.